Calidi Biotherapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Calidi Biotherapeutics, Inc. (CLDI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.87 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $1.87, a 97.24% decline year-over-year.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $2.67, a 72.19% decline year-over-year.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $67.68, a 283.67% increase year-over-year.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $7.80, a 30.36% decline year-over-year.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $3.11, a 82.00% decline from fiscal 2024.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $17.28, a 59.72% decline from fiscal 2023.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $42.90, a 526.28% increase from fiscal 2022.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $6.85.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.87 10-Q · filed 2026-08-13 | $1.87 10-Q · filed 2026-08-13 | ||||||
| 2025-12-31 | $3.11 10-K · filed 2026-03-27 | |||||||
| 2025-09-30 | $2.67 10-Q · filed 2025-11-13 | $3.11 10-Q · filed 2025-11-13 | ||||||
| 2025-06-30 | $67.68 10-Q · filed 2026-08-13 | $4.23 10-Q · filed 2025-08-08 | $68.00 10-Q · filed 2026-08-13 | $4.25 10-Q · filed 2025-08-08 | ||||
| 2025-03-31 | $7.80 10-Q · filed 2026-05-14 | $0.65 10-Q · filed 2025-05-14 | ||||||
| 2024-12-31 | $17.28 10-K · filed 2026-03-27 | $1.44 10-K · filed 2025-03-31 | ||||||
| 2024-09-30 | $9.60 10-Q · filed 2025-11-13 | $0.80 10-Q · filed 2024-11-12 | $17.52 10-Q · filed 2025-11-13 | $1.46 10-Q · filed 2024-11-12 | ||||
| 2024-06-30 | $17.64 10-Q · filed 2025-08-08 | $1.47 10-Q · filed 2024-08-13 | $21.84 10-Q · filed 2025-08-08 | $1.82 10-Q · filed 2024-08-13 | ||||
| 2024-03-31 | $11.20 10-Q · filed 2025-05-14 | $1.12 10-Q · filed 2024-05-14 | ||||||
| 2023-12-31 | $42.90 10-K · filed 2025-03-31 | $4.29 10-K · filed 2024-03-15 | ||||||
| 2023-09-30 | $6.63 10-Q · filed 2024-11-12 | $5.36 10-Q · filed 2024-11-12 | ||||||
| 2023-06-30 | $53.32 10-Q · filed 2024-08-13 | $53.52 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | $5.36 10-Q · filed 2024-05-14 | |||||||
| 2022-12-31 | $6.85 10-K · filed 2024-03-15 | |||||||
| 2022-09-30 | $6.87 10-Q · filed 2023-11-14 | $6.85 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |